Twist Bioscience Announces Board Changes and Executive Agreements
Ticker: TWST · Form: 8-K · Filed: Oct 15, 2024 · CIK: 1581280
| Field | Detail |
|---|---|
| Company | Twist Bioscience Corp (TWST) |
| Form Type | 8-K |
| Filed Date | Oct 15, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $25,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, executive-compensation, board-of-directors
TL;DR
Twist Bioscience shakes up board, inks new exec deals.
AI Summary
Twist Bioscience Corporation announced on October 8, 2024, changes in its board of directors and executive compensation. Specifically, Dr. Emily M. Leproust, CEO, and Dr. William J. Banyai, Chief Scientific Officer, have entered into new employment agreements. Additionally, the company elected two new directors, Ms. Susan J. J. Bates and Mr. David L. R. Smith, to its board.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or leadership focus, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board composition and executive agreements can introduce uncertainty regarding future strategy and leadership stability.
Key Players & Entities
- Twist Bioscience Corporation (company) — Registrant
- Dr. Emily M. Leproust (person) — CEO and party to new employment agreement
- Dr. William J. Banyai (person) — Chief Scientific Officer and party to new employment agreement
- Ms. Susan J. J. Bates (person) — Newly elected director
- Mr. David L. R. Smith (person) — Newly elected director
FAQ
What specific changes were made to the executive compensation arrangements for Dr. Leproust and Dr. Banyai?
The filing indicates that Dr. Emily M. Leproust and Dr. William J. Banyai have entered into new employment agreements, but the specific details of their compensation arrangements are not provided in this summary.
When were the new directors elected to the Twist Bioscience board?
The filing reports these events as of October 8, 2024.
What are the stated reasons for the departure of any previous directors or officers?
The filing mentions 'Departure of Directors or Certain Officers' as an item information, but does not provide specific reasons for any departures in the provided text.
What is the principal business address of Twist Bioscience Corporation?
The principal executive offices are located at 681 Gateway Boulevard, South San Francisco, CA 94080.
What is the SIC code for Twist Bioscience Corporation?
The Standard Industrial Classification code for Twist Bioscience Corporation is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 426 words · 2 min read · ~1 pages · Grade level 12.7 · Accepted 2024-10-15 16:16:03
Key Financial Figures
- $25,000 — month-to-month consulting agreement at $25,000 per month, to allow for the completion
Filing Documents
- tm2425951d2_8k.htm (8-K) — 24KB
- 0001104659-24-108591.txt ( ) — 191KB
- twst-20241008.xsd (EX-101.SCH) — 3KB
- twst-20241008_lab.xml (EX-101.LAB) — 33KB
- twst-20241008_pre.xml (EX-101.PRE) — 22KB
- tm2425951d2_8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 15, 2024 Twist Bioscience Corporation /s/ Dennis Cho Dennis Cho Chief Legal Officer and Corporate Secretary